ATE282041T1 - Aminomethylpyrrolochinazoline als thrombinrezeptor-antagonist - Google Patents

Aminomethylpyrrolochinazoline als thrombinrezeptor-antagonist

Info

Publication number
ATE282041T1
ATE282041T1 AT02706040T AT02706040T ATE282041T1 AT E282041 T1 ATE282041 T1 AT E282041T1 AT 02706040 T AT02706040 T AT 02706040T AT 02706040 T AT02706040 T AT 02706040T AT E282041 T1 ATE282041 T1 AT E282041T1
Authority
AT
Austria
Prior art keywords
aminomethylpyrrolochinazoline
thrombin receptor
receptor antagonist
par
methods
Prior art date
Application number
AT02706040T
Other languages
English (en)
Inventor
Bruce E Maryanoff
Han-Cheng Zhang
David F Mccomsey
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Application granted granted Critical
Publication of ATE282041T1 publication Critical patent/ATE282041T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT02706040T 2001-02-23 2002-01-29 Aminomethylpyrrolochinazoline als thrombinrezeptor-antagonist ATE282041T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27098801P 2001-02-23 2001-02-23
PCT/US2002/002489 WO2002068425A1 (en) 2001-02-23 2002-01-29 Aminomethyl-pyrroloquinazoline compounds as thrombin receptor antagonists
US10/059,707 US6740657B2 (en) 2001-02-23 2002-01-29 Aminomethyl-pyrroloquinazoline compounds as thrombin receptor antagonists

Publications (1)

Publication Number Publication Date
ATE282041T1 true ATE282041T1 (de) 2004-11-15

Family

ID=26739081

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02706040T ATE282041T1 (de) 2001-02-23 2002-01-29 Aminomethylpyrrolochinazoline als thrombinrezeptor-antagonist

Country Status (7)

Country Link
US (1) US6740657B2 (de)
EP (1) EP1370560B1 (de)
JP (1) JP2005500253A (de)
AT (1) ATE282041T1 (de)
DE (1) DE60201892T2 (de)
ES (1) ES2232735T3 (de)
WO (1) WO2002068425A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
AU2003247754A1 (en) * 2002-06-26 2004-01-19 Entremed, Inc Compositions and methods comprising protein activated receptor antagonists
US7226915B2 (en) * 2003-05-15 2007-06-05 Hoffmann-La Roche Inc. Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors
US7262297B2 (en) * 2003-05-15 2007-08-28 Hoffmann-La Roche Inc. Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors
WO2006023844A2 (en) * 2004-08-20 2006-03-02 Entremed, Inc. Compositions and methods comprising proteinase activated receptor antagonists
US7253177B2 (en) 2004-10-22 2007-08-07 United States Of America As Represented By The Secretary Of The Army Synthesis and antimalarial activity of pyrrolo[3,2-f]quinazoline-1,3-diamine derivatives
WO2006046949A1 (en) * 2004-10-22 2006-05-04 Walter Reed Army Institute Of Research (Wrair) SYNTHESIS AND ANTIMALARIAL ACTIVITY OF PYRROLO[3,2-f]QUINAZOLINE-1,3- DIAMINE DERIVATIVES
TWI367112B (en) * 2006-06-30 2012-07-01 Schering Corp Immediate-release tablet formulations of a thrombin receptor antagonist
TWI343262B (en) * 2006-09-26 2011-06-11 Schering Corp Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist
EP2982756A1 (de) * 2014-08-04 2016-02-10 Berlin Cures Holding AG Aptamere zur Verwendung gegen Erkrankungen im Zusammenhang mit Autoantikörpern
EP4175958A4 (de) * 2020-07-02 2024-07-17 The Trustees of Princeton University Verbindungen mit antikrebswirkung

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4118561A (en) 1977-04-06 1978-10-03 American Home Products Corporation 7-(Substituted)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamines
US4208520A (en) 1978-06-28 1980-06-17 American Home Products Corporation 7-(Substituted)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamines
US4451466A (en) 1982-07-02 1984-05-29 Shell Oil Company Use of pyrroloquinazolinediamines as pesticides
GB9123916D0 (en) * 1991-11-11 1992-01-02 Wellcome Found Heterocyclic compounds
US6653471B2 (en) * 2000-08-07 2003-11-25 Neurogen Corporation Heterocyclic compounds as ligands of the GABAA receptor

Also Published As

Publication number Publication date
JP2005500253A (ja) 2005-01-06
DE60201892D1 (en) 2004-12-16
WO2002068425A1 (en) 2002-09-06
EP1370560B1 (de) 2004-11-10
US6740657B2 (en) 2004-05-25
EP1370560A1 (de) 2003-12-17
US20020160963A1 (en) 2002-10-31
DE60201892T2 (de) 2005-11-03
ES2232735T3 (es) 2005-06-01

Similar Documents

Publication Publication Date Title
ATE463495T1 (de) Oxadiazolylpyrazolopyrimidine als mglur2- antagonisten
SE0202241D0 (sv) Novel Compounds
DE69940063D1 (de) Biphenylsulfonamide als zweifach aktive rezeptor antagonisten von angiotensin und endothelin
BG66084B1 (bg) Циклопентаноиндоли, състави,съдържащи такива съединения и използването им
DE60222396D1 (de) N-(2-arylethyl) benzylamine als 5-ht6 rezeptor-antagoniste
ATE382353T1 (de) Substiuierte piperidine als melanocortinrezeptor- modulatoren
NO20072435L (no) CGRP-reseptorantagonister
DE60212146D1 (de) Piperidin derivate als ccr5 rezeptor antagonisten zur behandlung von hiv
TR200100267T2 (tr) İkameli anilid bileşimleri ve yöntemler.
ATE466860T1 (de) Cgrp-rezeptorantagonisten
WO2007079214A3 (en) Prokineticin 2 receptor antagonists
ATE334965T1 (de) Piperidinverbindungen als muscarinantagonisten
ATE282041T1 (de) Aminomethylpyrrolochinazoline als thrombinrezeptor-antagonist
DE602005027230D1 (de) Cgrp-rezeptorantagonisten
MY153719A (en) Prokineticin 1 receptor antagonists
MX2007011847A (es) Derivados de pirimidindiona como antagonistas del receptor de procineticina 2.
TW200531686A (en) Pharmaceutical compositions
IS8377A (is) Arýlindenópyridín og arýlindenópyrimidín og notkun þeirra sem mótlyf A2A viðtaka adenósíns
BR0307156A (pt) Derivado de pirimidina bicìclica fundida, composto, antagonistas de receptores e agentes profiláticos e terapêuticos
NZ514696A (en) IL-8 receptor antagonists
DE602005027870D1 (de) Cgrp-rezeptorantagonisten
SE0001373D0 (sv) NPY Y1 receptor agonists and antagonists
MY143477A (en) Il-8 receptor antagonists
BR0317363A (pt) Antagonista de npy-5
SE0001631D0 (sv) New use

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties